Back to Search
Start Over
Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?
- Source :
-
European journal of heart failure [Eur J Heart Fail] 2003 Jun; Vol. 5 (3), pp. 381-9. - Publication Year :
- 2003
-
Abstract
- Background: Multidisciplinary care (MDC) of heart failure (HF) can significantly reduce rates of unplanned hospitalisation, the major cost component of HF care.<br />Aims: This prospective, randomised, controlled study examines the cost-benefits of MDC of HF in the setting of optimal medical care.<br />Methods: 98 NYHA class IV HF patients (mean age 70.8+/-10.5 years) were randomised to MDC (n=51) or routine care (RC; n=47) of HF. A direct intervention cost was calculated from contact time (scheduled and unscheduled) spent by the MDC team. Unplanned hospitalisation costs for HF were calculated at a daily rate of 242. Outcomes were determined in monetary terms, i.e. the cost of the service per hospitalisation prevented and net costs/savings at 3 months.<br />Results: The direct intervention cost of the MDC team was 5860, with an average cost per patient of 113 (95% Cl: 97-128). At 3 months, there were a total of 12 unplanned HF readmissions in the RC group (25.5% rate, 195 days) compared to 2 in the MDC group (3.9% rate, 17 days). The number needed to treat to prevent one hospitalisation for HF was 6 over 3 months. The cost of the service per hospitalisation prevented was 586. The intervention produced a net cost saving of 37,216 for 51 patients treated over 3 months. Sensitivity analyses using 50% variation in costs and lower relative risk reductions confirmed the cost-benefits of the intervention.<br />Conclusion: MDC of HF remains cost-beneficial when combined with optimal, medical care. The significant clinical and cost-benefits suggest that this intensive approach to MDC and medical management should become the standard of care for HF.
- Subjects :
- Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors administration & dosage
Angiotensin-Converting Enzyme Inhibitors economics
Cost-Benefit Analysis economics
Decision Making
Digoxin administration & dosage
Digoxin economics
Diuretics administration & dosage
Diuretics economics
Dose-Response Relationship, Drug
Female
Furosemide administration & dosage
Furosemide economics
Heart Failure diagnosis
Heart Failure therapy
Hospitalization economics
Humans
Ireland
Length of Stay economics
Male
Middle Aged
Perindopril administration & dosage
Perindopril economics
Prospective Studies
Time Factors
Ventricular Dysfunction, Left diagnosis
Ventricular Dysfunction, Left economics
Ventricular Dysfunction, Left therapy
Health Care Costs
Heart Failure economics
Subjects
Details
- Language :
- English
- ISSN :
- 1388-9842
- Volume :
- 5
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- European journal of heart failure
- Publication Type :
- Academic Journal
- Accession number :
- 12798838
- Full Text :
- https://doi.org/10.1016/s1388-9842(02)00235-0